An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Velan Capital Investment Management and Repertoire Partners, holding approximately 7.7% of Radius Health's outstanding shares, announced their withdrawal of director nominations following a proposed sale to Gurnet Point Capital and Patient Square Capital. They believe the sale price does not fully reflect the value of the company and its assets, but express satisfaction that their involvement may help stockholders recover some lost value under the current Board of Directors. They also thanked their qualified director candidates and supporters.
Positive
Stockholders may recoup some value lost under the current Board.
Director nominations withdrawn may lead to a more stable governance structure.
Negative
Proposed sale price considered inadequate, potentially undervaluing the company and its assets.
Sale Announcement Follows Successful Velan-Repertoire Campaign Featuring Three World-Class Director Candidates
ALPHARETTA, Ga.--(BUSINESS WIRE)--
Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today released the following statement:
“While we believe that the proposed sale to Gurnet Point Capital and Patient Square Capital does not reflect the full price of the Company and its assets, we are pleased that our involvement drove an outcome that ultimately should allow stockholders to recoup a portion of the value that has been lost under Radius’ current Board of Directors.
As a result, we are withdrawing our director nominations. We are grateful to our exceptionally qualified director candidates Eric Ende, Cynthia Flowers, and Ann MacDougall for their time, expertise, and dedication to improving the Radius Board of Directors. We would also like to thank the fellow stockholders who supported us and our nominees both privately and publicly.”
What is the recent announcement regarding Radius Health (RDUS)?
Velan Capital and Repertoire Partners announced their withdrawal of director nominations after a proposed sale to Gurnet Point Capital and Patient Square Capital, believing the sale does not reflect Radius Health's full value.
What percentage of Radius Health's shares do Velan and Repertoire hold?
Together, Velan Capital and Repertoire Partners hold approximately 7.7% of Radius Health's outstanding shares.
What were the proposed buyers for Radius Health?
The proposed buyers for Radius Health are Gurnet Point Capital and Patient Square Capital.
Why did Velan Capital withdraw their director nominations?
Velan Capital withdrew their director nominations because they were pleased that their involvement led to a sale outcome that could help stockholders recover some value.
